Lyrica
PreclinicalSmall molecule
Lyrica is one of 57 small molecule programs targeting Mucositis. It is currently in Preclinical.
2
Indications
16
Total Trials
0
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
87 competitors in Epilepsy
#DrugCompanyPhaseTrials
1Vimpat
UCBApproved
Fycompa
CCatalyst Biosciences
Approved
Ritalin
NovartisApproved
Briviact
UCBPhase 3
Dilantin
VViatris Specialty LLC
Approved
Epidiolex
Jazz PharmaceuticalsPhase 3
Ketalar
AAultman Health Foundation
Approved
Advil
KKenvue Brands
Approved
Coreg
Akero TherapeuticsApproved
Glucophage
EMD SeronoApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Neuropathic Pain2 trials
Spinal Cord Injury1 trial
Peripheral Neuropathy1 trial
9 more indications
Ankle Surgery1 trial
Fibromyalgia1 trial
Seizure1 trial
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00351611·187 enrolled
Mucositis1 trial
A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.
Completed·—·N/A·NCT02277548·20 enrolled
Postherpetic Neuralgia1 trial
Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT01455428·223 enrolled
Adult1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lyrica. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details